Thrombosis Drugs Market Size, Share & Trends Analysis Report By Disease Type (Deep Vein Thrombosis, Pulmonary Embolism), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
Description
Thrombosis Drugs Market Summary
The global thrombosis drugs market size was estimated at USD 26.11 billion in 2024 and is projected to reach USD 52.30 billion by 2033, growing at a CAGR of 8.03% from 2025 to 2033. The growth of this market is primarily driven by the high prevalence of cardiovascular diseases (CVDs) worldwide, as conditions such as heart attack, stroke, and venous thromboembolism (VTE) increase the demand for effective anticoagulant therapies.
An aging global population further contributes to market growth, since older adults are more susceptible to thrombosis and related complications. Advances in anticoagulant therapies, including safer and more convenient oral options, improve patient outcomes and encourage wider adoption. In addition, the rising prevalence of lifestyle-related diseases such as obesity, diabetes, and hypertension, combined with growing awareness of thrombosis risks and increased healthcare expenditure, continues to support sustained market expansion.
Product innovation and regulatory approvals drive the thrombosis drugs industry by expanding treatment options and raising clinician confidence. Recent drug and device advances, including faster, easier-to-administer clot-dissolving medicines and improved oral anticoagulants, make treatment more effective and simpler to deliver, which supports market growth by increasing clinical uptake. For instance, in March 2025, Genetech's TNKase, a clot-dissolving agent, received the U.S. Food and Drug Administration (FDA) approval for treating acute ischemic stroke (AIS). It is delivered as a single five-second intravenous (IV) bolus, providing a quicker and simpler option than the standard Activase, which requires an IV bolus followed by a 60-minute infusion.
Global awareness initiatives, such as World Thrombosis Day, organized by the International Society on Thrombosis and Hemostasis (ISTH), help to highlight the importance of thrombosis prevention and early detection, thereby indirectly supporting the thrombosis drugs market.
Global Thrombosis Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global thrombosis drugs market report based on disease type, drug class, distribution channel, and region:
To learn more about this report, Download Free Sample Report
The global thrombosis drugs market size was estimated at USD 26.11 billion in 2024 and is projected to reach USD 52.30 billion by 2033, growing at a CAGR of 8.03% from 2025 to 2033. The growth of this market is primarily driven by the high prevalence of cardiovascular diseases (CVDs) worldwide, as conditions such as heart attack, stroke, and venous thromboembolism (VTE) increase the demand for effective anticoagulant therapies.
An aging global population further contributes to market growth, since older adults are more susceptible to thrombosis and related complications. Advances in anticoagulant therapies, including safer and more convenient oral options, improve patient outcomes and encourage wider adoption. In addition, the rising prevalence of lifestyle-related diseases such as obesity, diabetes, and hypertension, combined with growing awareness of thrombosis risks and increased healthcare expenditure, continues to support sustained market expansion.
Product innovation and regulatory approvals drive the thrombosis drugs industry by expanding treatment options and raising clinician confidence. Recent drug and device advances, including faster, easier-to-administer clot-dissolving medicines and improved oral anticoagulants, make treatment more effective and simpler to deliver, which supports market growth by increasing clinical uptake. For instance, in March 2025, Genetech's TNKase, a clot-dissolving agent, received the U.S. Food and Drug Administration (FDA) approval for treating acute ischemic stroke (AIS). It is delivered as a single five-second intravenous (IV) bolus, providing a quicker and simpler option than the standard Activase, which requires an IV bolus followed by a 60-minute infusion.
Global awareness initiatives, such as World Thrombosis Day, organized by the International Society on Thrombosis and Hemostasis (ISTH), help to highlight the importance of thrombosis prevention and early detection, thereby indirectly supporting the thrombosis drugs market.
Global Thrombosis Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global thrombosis drugs market report based on disease type, drug class, distribution channel, and region:
To learn more about this report, Download Free Sample Report
- Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- Factor Xa Inhibitors
- Thrombin Inhibitors
- Heparins
- P2Y12 Platelet Inhibitors
- Others
- Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Disease Type
- 1.2.2. Drug Class
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Thrombosis Drugs Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- Chapter 4. Thrombosis Drugs Market: Disease Type Business Analysis
- 4.1. Disease Type Market Share, 2024 & 2033
- 4.2. Disease Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
- 4.4. Deep Vein Thrombosis
- 4.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.5. Pulmonary Embolism
- 4.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.6. Atrial Fibrillation
- 4.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Thrombosis Drugs Market: Drug Class Business Analysis
- 5.1. Drug Class Market Share, 2024 & 2033
- 5.2. Drug Class Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
- 5.4. Factor Xa Inhibitors
- 5.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 5.5. Thrombin Inhibitors
- 5.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 5.6. Heparins
- 5.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 5.7. P2Y12 Platelet Inhibitors
- 5.7.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 5.8. Others
- 5.8.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Thrombosis Drugs Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Thrombosis Drugs Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
- 7.4. North America
- 7.4.1. North America Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Disease Prevalence
- 7.4.2.3. Regulatory Framework/Reimbursement Framework
- 7.4.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Disease Prevalence
- 7.4.3.3. Regulatory Framework/Reimbursement Framework
- 7.4.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Disease Prevalence
- 7.4.4.3. Regulatory Framework/Reimbursement Framework
- 7.4.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Disease Prevalence
- 7.5.2.3. Regulatory Framework/Reimbursement Framework
- 7.5.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Disease Prevalence
- 7.5.3.3. Regulatory Framework/Reimbursement Framework
- 7.5.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Disease Prevalence
- 7.5.4.3. Regulatory Framework/Reimbursement Framework
- 7.5.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Disease Prevalence
- 7.5.5.3. Regulatory Framework/Reimbursement Framework
- 7.5.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Disease Prevalence
- 7.5.6.3. Regulatory Framework/Reimbursement Framework
- 7.5.6.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Disease Prevalence
- 7.5.7.3. Regulatory Framework/Reimbursement Framework
- 7.5.7.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Disease Prevalence
- 7.5.8.3. Regulatory Framework/Reimbursement Framework
- 7.5.8.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Disease Prevalence
- 7.5.9.3. Regulatory Framework/Reimbursement Framework
- 7.5.9.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Disease Prevalence
- 7.6.2.3. Regulatory Framework/Reimbursement Framework
- 7.6.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Disease Prevalence
- 7.6.3.3. Regulatory Framework/Reimbursement Framework
- 7.6.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Disease Prevalence
- 7.6.4.3. Regulatory Framework/Reimbursement Framework
- 7.6.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Disease Prevalence
- 7.6.5.3. Regulatory Framework/Reimbursement Framework
- 7.6.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Disease Prevalence
- 7.6.6.3. Regulatory Framework/Reimbursement Framework
- 7.6.6.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Disease Prevalence
- 7.6.7.3. Regulatory Framework/Reimbursement Framework
- 7.6.7.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Disease Prevalence
- 7.7.2.3. Regulatory Framework/Reimbursement Framework
- 7.7.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Disease Prevalence
- 7.7.3.3. Regulatory Framework/Reimbursement Framework
- 7.7.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Disease Prevalence
- 7.8.2.3. Regulatory Framework/Reimbursement Framework
- 7.8.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Disease Prevalence
- 7.8.3.3. Regulatory Framework/Reimbursement Framework
- 7.8.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Disease Prevalence
- 7.8.4.3. Regulatory Framework/Reimbursement Framework
- 7.8.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Disease Prevalence
- 7.8.5.3. Regulatory Framework/Reimbursement Framework
- 7.8.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Bristol-Myers Squibb Company
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Johnson & Johnson
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Boehringer Ingelheim International GmbH
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. SANOFI
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. AstraZeneca
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Pfizer Inc.
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. CSL
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Novo Nordisk A/S
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Takeda Pharmaceutical Company Limited
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Ionis Pharmaceuticals
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.11. Grifols, S.A.
- 8.5.11.1. Overview
- 8.5.11.2. Financial Performance
- 8.5.11.3. Product Benchmarking
- 8.5.11.4. Strategic Initiatives
- 8.5.12. Aspen Holdings
- 8.5.12.1. Overview
- 8.5.12.2. Financial Performance
- 8.5.12.3. Product Benchmarking
- 8.5.12.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
